Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 225-097-9 | CAS number: 4657-00-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Start of experimental phase: 25 September 2017 End of experimental phase: 19 October 2017 Study completion: 18 January 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- adopted on 17 December 2001
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Version / remarks:
- described in
Council Regulation (EC) No. 440/2008 and subsequent revisions - Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: EPA, OPPTS Methods 870.1000 "Acute Toxicity Testing - Background"
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- no
Test material
- Reference substance name:
- 1,3,3-trimethyl-2-[2-(1-methyl-2-phenyl-1H-indol-3-yl)vinyl]-3H-indolium chloride
- EC Number:
- 225-097-9
- EC Name:
- 1,3,3-trimethyl-2-[2-(1-methyl-2-phenyl-1H-indol-3-yl)vinyl]-3H-indolium chloride
- Cas Number:
- 4657-00-5
- Molecular formula:
- C28H27N2.Cl
- IUPAC Name:
- 1,3,3-trimethyl-2-[(E)-2-(1-methyl-2-phenyl-1H-indol-3-yl)ethenyl]-3H-indol-1-ium chloride
- Test material form:
- solid: particulate/powder
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
Species and strain: Rat, Hsd: Sprague Dawley SD
Sex: Females (nulliparous and non-pregnant)
Age:7 weeks old
Supplier: Envigo RMS s.r.l., San Pietro al Natisone (UD), Italy
Breeder: Envigo RMS B.V., Kreuzelweg 53, 5961 NM Horst, Netherlands
Date of arrival: 13 September 2017
Weight range at arrival: 162.6-176.3 grams
Acclimatisation period: At least 5 days
Veterinary health check: During acclimatisation period
ENVIRONMENTAL CONDITIONS
Animals per cage: 3 during the study; 5 during acclimatisation
Housing: Polisulfone solid bottomed cages measuring 59.5×38×20 cm with nesting material provided into suitable bedding bags
Cage control: Daily inspected and changed as necessary (at least 3 times/week)
Water Drinking: water supplied to each cage via a water bottle
Water supply: ad libitum
Diet: 4 RF 18 (Mucedola S.r.l., Via G. Galilei, 4, 20019, Settimo Milanese (MI) Italy)
Diet supply: ad libitum throughout the study except for the dosing procedure indicated in section 4.2.2
Room lighting: Artificial (fluorescent tubes), daily light/dark cycle of 12/12 hours
Air changes: Approximately 15 to 20 air changes per hour
Temperature range: 22 °C±2 °C
Relative humidity range: 55%±15%
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 30 and 5mg/mL.
- Amount of vehicle (if gavage): 10 mL/kg
- Doses:
- 300 mg/kg; 50 mg/kg
- No. of animals per sex per dose:
- 3 Females at 300 mg/kg; 6 females at 50 mg/kg
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Animals were observed for clinical signs as indicated: Day of dosing: on dosing, approximately 0.5 hour after dosing, approximately 2 hours after dosing, approximately 4 hours after dosing, daily thereafter for a total of 14 days. All animals were weighed at allocation to the study (Day -1), on the day of dosing (Day 1) and
on Days 2, 8 and 15.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight
Results and discussion
Effect levels
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 50 - < 300 mg/kg bw
- Based on:
- test mat. (total fraction)
- Mortality:
- All animals dosed at 300mg/kg bodyweight were found dead after a few minutes from the administration.
One animal dosed at 50mg/kg bodyweight was found dead in cage at 2 hours after dosing.
In the second group dosed with 50mg/kg bodyweight, one animal was found dead in cage 2
hours after dosing. - Clinical signs:
- All animals dosed at 300mg/kg bodyweight appeared prone at observation performed at 30 minutes after dosing and died after few minutes.
One animal dosed at 50 mg/kg body weight, found dead at 2 hours after dosing, did not show any clinical sign. One animal, dosed at 50 mg/kg body weight,
showed decreased activity 30 minutes after dosing and was found dead at 2 hours after dosing.
Hunched posture and piloerection were observed in two animals dosed at 50 mg/kg body weight at 2 and 4 hours after dosing. These signs recovered on Day 2 of study. Two animal dosed at the same dose level did not show any clinical sign. - Body weight:
- Changes in body weight observed during the study were within the expected range for this strain and age of animals.
- Gross pathology:
- Unscheduled deaths:
Orange mucosa and orange mucoid content in duodenum, jejunum and stomach and orange staining on the muzzle were observed in all early deceased animals
treated at 300mg/kg bodyweight. In addition, single animals showed abnormal colour and contents (orange mucosa and orange mucoid, respectively) in ileum
(animal nos. 191 and 195) and red mucosa of the caecum (animal no. 191). Abnormal colour and/or abnormal contents in duodenum, jejunum and stomach were observed in early deceased animals treated at 50mg/kg bodyweight. Moreover, orange fluid in ileum was observed in animal no. 201 and dark colour of the liver,
swollen spleen, dark red pancreas, multiple dark red pinpoint on thymus, dark colour of mesenteric lymph nodes, orange staining on muzzle and brown
staining on urogenital region in animal no. 207.
Final sacrifice:
No abnormalities were observed at necropsy examination performed at the end of the observation period on animals treated at 50mg/kg bodyweight.
Applicant's summary and conclusion
- Interpretation of results:
- Category 3 based on GHS criteria
- Conclusions:
- The acute toxicity of Basic Orange 22 was investigated following a single oral administration (10 mL/kg bodyweight in purified water) to the Sprague Dawley rat
followed by a 14-day observation period.
All animals treated at 300 mg/kg bodyweight died. At 50 mg/kg bodyweight, two animals out of 6 died. Piloerection, hunched posture and decreased activity were observed in 2 of the surviving animals following dosing at 50 mg/kg bodyweight.
These results demonstrate the expected acute oral LD50 of Basic Orange 22 to be lower than 300 mg/kg bodyweight, but higher than 50 mg/kg bodyweight. - Executive summary:
The acute toxicity of Basic Orange 22 was investigated following a single oral administration to the Sprague Dawley rat followed by a 14-day observation period. A first group of 3 female animals was initially dosed at 300 mg/kg bodyweight (Step 1). All animals died on the day of dosing. The animals appeared prone at observation performed at 30 minutes after dosing and died after few minutes.
A second group of 3 female animals was then dosed at 50 mg/kg bodyweight (Step 2). One animal showed decreased activity 30 minutes after dosing and was found dead at 2 hours after dosing.
Hunched posture and piloerection were observed in one animal at 2 and 4 hours after dosing. These signs recovered on Day 2 of study. The third animal in this group did not show any clinical sign. A third group, similarly composed, was then dosed at the same dose level (Step 3). One animal was found dead 2 hours after dosing. A single animal showed piloerection, hunched posture and decreased activity at 2 and 4 hours after dosing. These signs recovered on Day 2 of study. The third animal did not show any clinical sign. Body weight changes recorded during the study were within the expected range for this strain and age of animals. Orange mucosa and orange mucoid content in duodenum, jejunum and stomach and orange staining on the muzzle were observed in all early deceased animals treated at 300 mg/kg bodyweight. In addition, single animals showed abnormal colour and contents (orange mucosa and orange mucoid, respectively) in ileum (animal nos.191 and 195) and red mucosa of the caecum (animal no. 191). Abnormal colour and/or abnormal contents in duodenum, jejunum and stomach were observed in early deceased animals treated at 50 mg/kg bodyweight. Moreover, orange fluid in ileum was observed in animal no. 201 and dark colour of the liver, swollen spleen, dark red pancreas, multiple dark red pinpoint on thymus, dark colour of mesenteric lymph nodes, orange staining on muzzle and brown staining on urogenital region in animal no. 207. No abnormalities were observed at necropsy examination performed at the end of the observation period on animals treated at 50mg/kg bodyweight. These results demonstrate the expected acute oral LD50 to be lower than 300 mg/kg bodyweight, but higher than 50 mg/kg bodyweight.
European Directives concerning the classification, packaging and labelling of dangerous substances (Council Regulation (EC)No. 1272/2008 and subsequent revisions) would indicate the following:
Classification Category 3
Signal word Danger
Hazard statement Toxic if swallowed
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.